Company intelligence / Profile preview

60 Degrees Pharmaceuticals

Washington, District of Columbia, United States60degreespharma.com ↗

Ownership: Public · SXTP
Development stage: Commercial

Overview

Successfully achieved FDA approval for ARAKODA® (tafenoquine) for malaria prevention in 2018, which has been on the market since late 2019. Reported 140% revenue growth in 2024, driven by Arakoda® sales. Currently conducting clinical trials and market expansion.

Therapeutic areas: Infectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

celgosivir

2 more assets in the full pipeline.

Request access →

Partnerships

U.S. Armyresearch organizations in the U.S., Australia, and Singapore

Beyond the preview

Go deeper on 60 Degrees Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 60 Degrees Pharmaceuticals.

Explore the full profile